Shuttle Pharmaceuticals

IN THE PRESS

Business

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

August 15, 2023

·

4 min read

BioCapital

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

August 3, 2023

·

3 min read

Business

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

May 26, 2023

·

8 min read

BioCapital

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023

·

2 min read

Deals

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

January 12, 2023

·

3 min read

BioCapital

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

December 6, 2022

·

4 min read

BioCapital

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol “SHPH”

August 31, 2022

·

6 min read

Deals

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering

August 30, 2022

·

3 min read

Business

Shuttle Pharmaceuticals Holdings, Inc. Announces Appointment of Chris Senanayake, PhD To Board of Directors

May 20, 2021

·

2 min read

BioCapital

Shuttle Pharmaceuticals, Inc. Awarded a New Patent for Dual Function HDAC Molecules for HDAC Inhibition and Ataxia Telangiectasia Mutated Activation for Cancer Treatment

November 4, 2020

·

3 min read

JOBS